BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone formation in the spine, leading to severe neurological symptoms due to spinal ...
Peking University, August 18, 2025: A research team led by Professor Wang Yangming from the Institute of Molecular Medicine, College of Future Technology, and the Beijing Advanced Center of RNA ...
Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...
A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...
Healthcare Asia Magazine on MSN
Lucence, DXD Hub, and NCCS launch $6m UNITED 2.0 cancer test
The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted by A*STAR, and the National Cancer Centre Singapore have launched UNITED 2.0 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results